



Amgen offer a process that allows a transplanting centre to purchase the first two doses of BEKEMV[®] ▼ (eculizumab) on a named renal transplant patient basis in advance of the drug being required.

If your trust has a patient pending or post activation for renal transplant and you need to order BEKEMV[®] to have stock available for this patient please follow steps below:

1

Contact your Amgen representative to request BEKEMV[®] for a patient pending or post activation for renal transplant:

hayleyw@amgen.com

Request the contract and provide name, title and e-mail address of signatory

2

Amgen will provide a contract that will detail the process for obtaining available stock for a renal transplant patient. This is to be signed by both the trust and Amgen via DocuSign

3

Trust to sign (this will then automatically return to Amgen post signature)

4

Following Amgen signature, a fully executed document will be returned to the trust

5

Once the contract is completed, BEKEMV[®] is ordered by the trust as per standard process (found in Appendix 1 of the completed contract). Please note, in parallel, an Amgen patient vaccination certificate is required – see link below

<https://www.medicines.org.uk/emc/rmm/2884/Document#gref>

6

This process is repeated for any patient that is pending imminent activation or becomes activated for renal transplant



To access BEKEMV[®] prescribing information [click here](#) or scan the above QR code

▼ This medicinal product is subject to additional monitoring.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on +44 (0) 1223 436441.